"Insulin Aspart" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.
| Descriptor ID |
D061267
|
| MeSH Number(s) |
D06.472.699.587.200.400.100 D12.644.548.586.200.400.100
|
| Concept/Terms |
Insulin Aspart- Insulin Aspart
- Aspart, Insulin
- Insulin, Aspartic Acid(B28)-
- Insulin B28asp
- B28asp, Insulin
- Insulin-Aspart
- B28-Asp-Insulin
- B28 Asp Insulin
|
Below are MeSH descriptors whose meaning is more general than "Insulin Aspart".
Below are MeSH descriptors whose meaning is more specific than "Insulin Aspart".
This graph shows the total number of publications written about "Insulin Aspart" by people in this website by year, and whether "Insulin Aspart" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin Aspart" by people in Profiles.
-
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017 07; 40(7):951-957.
-
Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014 Mar; 16(3):193-205.
-
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012 Jun 15; 11(12):2314-26.
-
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1498-507.
-
Severe autoimmune insulin resistance--a case report. QJM. 2014 Dec; 107(12):1019-21.
-
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab. 2007 Jan; 9(1):103-13.
-
Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006; 66(1):31-49.
-
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006 Jan; 8(1):58-66.
-
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005 Feb; 28(2):260-5.
-
Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes. Clin Ther. 2005; 27 Suppl B:S39-41.